Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Jul 11, 2021 12:48pm
264 Views
Post# 33527789

RE:Investor Presentation has been updated on their website.

RE:Investor Presentation has been updated on their website.I have looked at the successive ONCY investor presentations for many years.

This is the best and most informative one they have ever had. That makes sense because they keep improving them. But the additional opportunities they mention are new and very encouraging.

Let us remember four things when feeling dismayed at the time this is all taking:

- we are entering the world of immunotherapy for cancer in multiple fronts, for multiple indications, with multiple approaches. Pela seems to stimulate the immune system to make all of them work better. That is the direction of all the findings so far.

-we are a company with a $150 mil market cap and $50 mil in the bank, with the prospect of entering markets worth billions annually. 

-we now have 20 years of science that demonstrates how, when and why pela works. 

-we have the best bug (safest, easiest to use) for immunotherapy. 
<< Previous
Bullboard Posts
Next >>